The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors.
 
Philippe Georges Aftimos
Honoraria - Synthon
 
Oliver Bechter
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Roche
 
Ahmad Awada
No Relationships to Disclose
 
Christiane Jungels
Travel, Accommodations, Expenses - Bayer; PharmaMar
 
Herlinde Dumez
Honoraria - Astellas Oncology; Roche
Travel, Accommodations, Expenses - Astellas Oncology; AstraZeneca; Bayer; Novartis; Roche; Sanofi
 
Nathalie Huyvaert
No Relationships to Disclose
 
Jo Costermans
No Relationships to Disclose
 
Chooi Lee
Employment - Boehringer Ingelheim
 
Marie-Anne Meeus
Employment - Boehringer Ingelheim
 
Ute Burkard
Employment - Boehringer Ingelheim
 
Hanny Musa
Employment - Boehringer Ingelheim
 
Yihua Zhao
Employment - Boehringer Ingelheim
 
Patrick Schoffski
Honoraria - Daiichi Sankyo; Eisai; Lilly; Medpace; Novartis; Swedish Orphan Biovitrum
Consulting or Advisory Role - 6th Element Capital; Adaptimmune; Amcure; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Cristal Therapeutics; Daiichi Sankyo; Eisai; Eisai; Epizyme; Epizyme; Genzyme; Genzyme; Ipsen; Ipsen; Lilly; Lilly; Loxo; Loxo; Medpace; Medpace; Nektar; Nektar; Novartis; Novartis; Philogen; Philogen; Pique; Pique; Plexxikon; Plexxikon
Speakers' Bureau - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Swedish Orphan Biovitrum
Research Funding - Bayer; Blueprint Medicines; CoBioRes NV; Exelixis; GlaxoSmithKline; Novartis; Plexxikon
Travel, Accommodations, Expenses - 6th Element Capital; Adaptimmune; Amcure; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Cristal Therapeutics; Cristal Therapeutics; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Epizyme; Epizyme; Genzyme; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Ipsen; Ipsen; Lilly; Lilly; Loxo; Loxo; Medpace; Medpace; Nektar; Nektar; Novartis; Novartis; PharmaMar; PharmaMar; Philogen; Philogen; Pique; Pique; Plexxikon; Plexxikon; Swedish Orphan Biovitrum; Swedish Orphan Biovitrum